AVING News interviewed Shin Gyeong-cheol, the CEO of Arcaeir, which participated in the MIK HOT SPOT (Made in Korea Online Exhibition) KHIDI.
Please introduce your company briefly.
The company was founded on June 29, 2013.
We separate and refine carotenoids mainly from marine microorganisms, and
develop the product to make drugs and health foods. Also, to screen the drugs,
we have developed a system called organ-on-chip, developing the equipment to screen
the drug's efficacy and toxicity.
Overview of major system
What we do is separating and refining
lansis beta-carotene with different isomers in carotenoids from marine
microorganisms for mass production. We have surpassed the technology that goes
beyond refining from natural products, and can now synthesize them.
Our synthesis technology boasts remarkable synthetic yields. Currently, it has
a purity of 99.9%, which is almost 100%. It is being developed for making
cardiovascular treatment drugs.
Currently, we have finished clinical
trials, and we aim to enter the commercial market within one to two years. And,
we use a rather different and difficult method for drug screening, which is to
use real human blood to stick the organ cells into the chip. By using blood
circulation, various efficacy or toxicity from it can be checked. This is the
system we are developing. The system is already in the second version. In the
third version, the blood cell measuring system will probably be included in the
Providing personalized drug service
screening to those who are developing new drugs or those with serious illnesses
is our short-term goal. In the long run, there are a lot of rare and
cardiovascular diseases opportunities because we are working on the
cardiovascular system. Especially for Marfan syndrome or something like this,
you have to be careful, or the heart may rupture. We are going to do research
in conjunction with genetic factors.
Now, we are developing version 2 with the development
of organ-on-chip already completed. We are now working on receiving approval on
the medical device. Until 2023, we are going to develop the system that has the
automatic blood cell measuring instrument attached to the organ-on-chip and see
the results. We are aiming at completing this by 2023. For version 3, what we
are going to do is to joint research with a company in Czech Republic.
Corporate value that we pursue
The corporate value we are striving for is
to focus on the chronic diseases or senile diseases. Above all, it is still not
clearly defined as to how such diseases started, and what procedure should be
taken to treat them. So basically, we first defined the cause of the illnesses,
and tried to find the ways to treat them. In the future, depending on the
cause, we are going to develop new methods that is not known yet. For example,
high fat accumulation in the cardiovascular diseases. They are the lipoproteins
coming out from the liver. This is the drug that inhibits by affecting the
liver due to this. Our drugs are blood vessel related drugs. So, even if we
change how we approach it slightly, we might have a more creative and new drugs
or treatment methods.
The value we strive for is a little
different and a little more professional. Going deeper into it. This is the
goal value we have.
Which of the KHIDI support program was helpful for you?
We made version1, and with the KHIDI
startup package support business, we finished version2. We have applied for a
patent. Now, we have IRB in Ajou University Hospital, and we are looking for
people to participate in the clinical trial. When we recruit them, the clinical
trial will be over before the second half of this year. With this, we are going
to apply for medical device approval for version 2.
We need version 3 to be fully automatic.
And the business goal we are pursuing is to develop the cardiovascular
treatment drugs and license out them after clinical approval. Already, several
global pharmaceutical companies are reviewing our projects and they want to
implement our system. This excites us.
The global news network AVING News has
begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small
and medium-sized companies enter the market and attract investment 365 days a
year. AVING News has been running online exhibitions since 2005 and had 975
online exhibitions so far. Its YouTube online exhibition has placed itself as
Korea's largest online exhibition hall that opens with 19,000 videos (booths)
with more than 800,000 visits per month which means more than 10 million visits
The MIK HOT SPOT online exhibition is
scheduled to be held regularly according to the field, target market, and
participating institutions, and it will be presented as a new type of online
business by transforming the know-hows and values of the participating
companies according to the trend. Companies that want to participate can apply
and apply through the marketing support projects from supporting institutions
in the local governments. Refer to the institutions for more information.